XTL Biopharmaceuticals Ltd ADR Net Assets
XTL Biopharmaceuticals Ltd ADR net assets. Based on the latest financial reports, XTL Biopharmaceuticals Ltd ADR (XTLB) has net assets worth $-254.00K USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($166.00K) and total liabilities ($420.00K). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore XTLB net assets growth trend to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-254.00K |
| % of Total Assets | -153.01% |
| Annual Growth Rate | N/A |
| 5-Year Change | -104.76% |
| 10-Year Change | -109.45% |
| Growth Volatility | 8236.61 |
Net Assets of XTL Biopharmaceuticals Ltd ADR (2002–2025)
Net assets of XTL Biopharmaceuticals Ltd ADR from 2002 to 2025. This chart illustrates how XTL Biopharmaceuticals Ltd ADR's net assets have evolved over time, based on quarterly financial data. See net asset quality index of XTL Biopharmaceuticals Ltd ADR to measure how much of total assets are equity-financed.
Annual Net Assets for XTL Biopharmaceuticals Ltd ADR (2002–2025)
The table below shows the annual net assets of XTL Biopharmaceuticals Ltd ADR from 2002 to 2025. For live market cap and overall valuation, see market value of XTL Biopharmaceuticals Ltd ADR.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $-254.00K | -104.67% |
| 2024-12-31 | $5.43 Million | +144.82% |
| 2023-12-31 | $2.22 Million | -44.49% |
| 2022-12-31 | $4.00 Million | -25.01% |
| 2021-12-31 | $5.33 Million | -14.66% |
| 2020-12-31 | $6.25 Million | -10.47% |
| 2019-12-31 | $6.98 Million | -16.13% |
| 2018-12-31 | $8.32 Million | +129.95% |
| 2017-12-31 | $3.62 Million | +34.69% |
| 2016-12-31 | $2.69 Million | -45.02% |
| 2015-12-31 | $4.89 Million | +4.45% |
| 2014-12-31 | $4.68 Million | -31.04% |
| 2013-12-31 | $6.79 Million | -28.00% |
| 2012-12-31 | $9.42 Million | +173.64% |
| 2011-12-31 | $3.44 Million | +21.52% |
| 2010-12-31 | $2.83 Million | +40385.71% |
| 2009-12-31 | $7.00K | -99.51% |
| 2008-12-31 | $1.43 Million | -83.35% |
| 2007-12-31 | $8.56 Million | -62.37% |
| 2006-12-31 | $22.76 Million | +102.28% |
| 2005-12-31 | $11.25 Million | -42.60% |
| 2004-12-31 | $19.60 Million | -4.88% |
| 2003-12-31 | $20.61 Million | -40.83% |
| 2002-12-31 | $34.83 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to XTL Biopharmaceuticals Ltd ADR's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 16563200000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
XTL Biopharmaceuticals Ltd ADR Net Assets Breakdown (December 2025)
XTL Biopharmaceuticals Ltd ADR net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $25.14 Million | % |
| Other Comprehensive Income | $20.00K | % |
| Other Components | $140.22 Million | % |
| Total Equity | $-254.00K | 100.00% |
XTL Biopharmaceuticals Ltd ADR Competitors by Market Cap
The table below lists competitors of XTL Biopharmaceuticals Ltd ADR ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
SOLUTIANCE AG NA O.N.
F:SLSA
|
$8.81 Million |
|
CS Corporation
KQ:065770
|
$8.81 Million |
|
Reliance Chemotex Industries Limited
NSE:RELCHEMQ
|
$8.81 Million |
|
Bermas SA
RO:BRM
|
$8.81 Million |
|
Equus Total Return Closed Fund
NYSE:EQS
|
$8.80 Million |
|
NEXE Innovations Inc
V:NEXE
|
$8.80 Million |
|
Niobay Metals Inc
V:NBY
|
$8.80 Million |
|
João Fortes Engenharia S.A.
SA:JFEN3
|
$8.79 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in XTL Biopharmaceuticals Ltd ADR's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 5,435,000 to -254,000, a change of -5,689,000 (-104.7%).
- Net loss of 6,969,000 reduced equity.
- Other factors increased equity by 1,280,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-6.97 Million | -2743.7% |
| Other Changes | $1.28 Million | +503.94% |
| Total Change | $- | -104.67% |
Book Value vs Market Value Analysis
This analysis compares XTL Biopharmaceuticals Ltd ADR's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2001-12-31 | $3746.52 | $2.45 | x |
| 2002-12-31 | $2507.02 | $2.45 | x |
| 2003-12-31 | $1475.79 | $2.45 | x |
| 2004-12-31 | $114.24 | $2.45 | x |
| 2005-12-31 | $53.41 | $2.45 | x |
| 2006-12-31 | $902.57 | $2.45 | x |
| 2007-12-31 | $299.85 | $2.45 | x |
| 2008-12-31 | $12.82 | $2.45 | x |
| 2009-12-31 | $0.06 | $2.45 | x |
| 2010-12-31 | $39.99 | $2.45 | x |
| 2011-12-31 | $27.01 | $2.45 | x |
| 2012-12-31 | $54.04 | $2.45 | x |
| 2013-12-31 | $44.83 | $2.45 | x |
| 2014-12-31 | $32.25 | $2.45 | x |
| 2015-12-31 | $29.65 | $2.45 | x |
| 2016-12-31 | $15.69 | $2.45 | x |
| 2017-12-31 | $12.32 | $2.45 | x |
| 2018-12-31 | $25.89 | $2.45 | x |
| 2019-12-31 | $21.72 | $2.45 | x |
| 2020-12-31 | $11.24 | $2.45 | x |
| 2021-12-31 | $13.86 | $2.45 | x |
| 2022-12-31 | $11.74 | $2.45 | x |
| 2023-12-31 | $6.52 | $2.45 | x |
| 2024-12-31 | $12.35 | $2.45 | x |
| 2025-12-31 | $-0.58 | $2.45 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently XTL Biopharmaceuticals Ltd ADR utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is below the historical average (1406.13%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2001 | -24.40% | 0.00% | 0.00x | 1.06x | $-17.87 Million |
| 2002 | -49.21% | 0.00% | 0.00x | 1.10x | $-20.62 Million |
| 2003 | -69.33% | 0.00% | 0.00x | 1.21x | $-16.35 Million |
| 2004 | -84.04% | -476.93% | 0.13x | 1.31x | $-18.43 Million |
| 2005 | -124.56% | -438.38% | 0.21x | 1.35x | $-15.14 Million |
| 2006 | -66.49% | -3333.04% | 0.02x | 1.18x | $-17.41 Million |
| 2007 | -291.21% | -2749.61% | 0.06x | 1.65x | $-25.80 Million |
| 2008 | -648.39% | -155.66% | 1.73x | 2.41x | $-9.39 Million |
| 2009 | 36957.14% | 0.00% | 0.00x | 102.14x | $2.59 Million |
| 2010 | -44.35% | 0.00% | 0.00x | 1.34x | $-1.54 Million |
| 2011 | -35.05% | 0.00% | 0.00x | 1.18x | $-1.55 Million |
| 2012 | -18.90% | -148.19% | 0.08x | 1.51x | $-2.13 Million |
| 2013 | -39.52% | -104.52% | 0.30x | 1.28x | $-3.10 Million |
| 2014 | -54.23% | -6163.41% | 0.01x | 1.21x | $-2.99 Million |
| 2015 | -88.21% | 0.00% | 0.00x | 1.09x | $-4.80 Million |
| 2016 | -94.72% | -11065.22% | 0.01x | 1.12x | $-2.81 Million |
| 2017 | -21.58% | -2693.10% | 0.00x | 1.82x | $-1.14 Million |
| 2018 | 35.88% | 5742.31% | 0.01x | 1.03x | $2.15 Million |
| 2019 | -19.30% | -1952.17% | 0.01x | 1.03x | $-2.04 Million |
| 2020 | -21.65% | -2792.86% | 0.00x | 1.80x | $-1.14 Million |
| 2021 | 8.16% | 29.67% | 0.22x | 1.24x | $-98.30K |
| 2022 | -33.71% | 0.00% | -0.11x | 1.05x | $-1.75 Million |
| 2023 | -0.08% | 0.00% | 0.00x | 1.09x | $-223.78K |
| 2024 | -18.90% | -227.72% | 0.05x | 1.57x | $-1.57 Million |
| 2025 | 0.00% | 0.00% | 0.00x | 0.00x | $-6.94 Million |
Industry Comparison
This section compares XTL Biopharmaceuticals Ltd ADR's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $-1,986,338
- Average return on equity (ROE) among peers: -54.96%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| XTL Biopharmaceuticals Ltd ADR (XTLB) | $-254.00K | -24.40% | N/A | $8.80 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $29.61 Million |
| Abcellera Biologics Inc (ABCL) | $11.61 Million | 2.66% | 0.85x | $3.53 Billion |
| Abeona Therapeutics Inc (ABEO) | $-26.99 Million | 0.00% | 0.00x | $248.75 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $70.43 Million | -172.28% | 0.74x | $15.17 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $-41.16 Million | 0.00% | 0.00x | $1.41 Billion |
| Arbutus Biopharma Corp (ABUS) | $-10.50 Million | 0.00% | 0.00x | $834.03 Million |
| ABVC Biopharma Inc (ABVC) | $4.59 Million | -357.76% | 1.38x | $26.65 Million |
| Abivax SA American Depositary Shares (ABVX) | $71.77 Million | -22.23% | 0.06x | $7.56 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $-22.51 Million | 0.00% | 0.00x | $3.55 Billion |
About XTL Biopharmaceuticals Ltd ADR
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases in Israel. Its lead drug candidate is hCDR1, which is a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. The company has a licensing agreement with Yeda Research and Development Company L… Read more